News
Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.
Show by Tag
Immunocidin is being evaluated in a clinical study as a palliative therapy for dogs with malignant cancer. The goal is to increase the dogs' comfort and maintain or improve the quality and duration of their remaining life.
Positive data from a retrospective study using Immunocidin® with chemotherapy in dogs with Lymphoma and Osteosarcoma were presented at the Veterinary Cancer Society Annual Conference by Dr. Jeannette Kelly, vet oncologist.
NovaVive's anticancer immunotherapeutic for dogs will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in the treatment of splenic hemangiosarcoma (in combination with chemo).
Dr. Jeannette Kelly, veterinary oncologist with Veterinary Cancer Care, presented data from a study of multiple IV administrations of Immunocidin® in dogs and cats with various malignancies at the ACVIM Forum last week.
The results of clinical studies using MCW formulations in ameliorating neutropenia and inducing serum cytokine synthesis were presented at the 3rd World Veterinary Cancer Congress (WVCC) in May, 2016 in Brazil.